Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026)

Viatris' (VTRS) quarterly Depreciation & Amortization (CF) came in at $676.1 million in Q1 2026, up 1.72% year-on-year from $664.7 million in Q1 2025, and down 11.83% quarter-over-quarter from $766.8 million in Q4 2025.

Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Viatris' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $676.1 million for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 1.72% year-over-year to $676.1 million in Q1 2026; TTM through Mar 2026 was $2.8 billion, a 2.0% decrease from a year earlier, with the FY2025 full-year figure at $2.8 billion, down 3.28% from the prior year.
  • Depreciation & Amortization (CF) slipped to $676.1 million in Q1 2026 per VTRS's latest filing, from $766.8 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $869.8 million in Q4 2022 and bottomed at $644.4 million in Q4 2023.
  • The 5-year median for Depreciation & Amortization (CF) is $691.0 million (2024), against an average of $713.9 million.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 16.0% in 2022; the steepest drop was 48.26% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $869.8 million in 2022, then slipped by 25.91% to $644.4 million in 2023, then gained by 15.8% to $746.2 million in 2024, then gained by 2.76% to $766.8 million in 2025, then retreated by 11.83% to $676.1 million in 2026.
  • Per Business Quant, the three latest VTRS Depreciation & Amortization (CF) figures stand at $676.1 million (Q1 2026), $766.8 million (Q4 2025), and $688.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 239.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 119.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 1.04 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 22.60 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 676.10 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 7.20 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 172.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 4.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 676.10 Mn
Mar 31, 2026 676.10 Mn
Dec 31, 2025 766.80 Mn
Dec 31, 2025 766.80 Mn
Sep 30, 2025 688.50 Mn
Sep 30, 2025 688.50 Mn
Jun 30, 2025 678.30 Mn
Jun 30, 2025 678.30 Mn
Mar 31, 2025 664.70 Mn
Mar 31, 2025 664.70 Mn
Dec 31, 2024 746.20 Mn
Dec 31, 2024 746.20 Mn
Sep 30, 2024 669.70 Mn
Sep 30, 2024 669.70 Mn
Jun 30, 2024 786.30 Mn
Jun 30, 2024 786.30 Mn
Mar 31, 2024 691.00 Mn
Mar 31, 2024 691.00 Mn
Dec 31, 2023 644.40 Mn
Dec 31, 2023 644.40 Mn